Preservative-free fixed combination in the treatment of open-angle glaucoma and ocular hypertension: the VISIONARY Study (EUPAS22204)

doi:https://doi.org/10.17116/oftalma202013604176

Journal: . 2020;136(4): 76‑84

DOI: 10.17116/oftalma202013604176

Read: 2648 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Preservative-free fixed combination in the treatment of open-angle glaucoma and ocular hypertension: the VISIONARY Study (EUPAS22204). . 2020;136(4):76‑84. (In Russ.)
https://doi.org/10.17116/oftalma202013604176

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)

Использование инфографики авторами научных работ

Close metadata

PURPOSE

To evaluate efficacy, tolerability, and safety of PF tafluprost/timolol FC in patients with primary open-angle glaucoma (POAG) and ocular hypertension (OH) who couldn’t tolerate or gave insufficient response to topical beta-adrenoblockers or prostaglandin analogue monotherapy.

MATERIAL AND METHODS

The prospective multicenter European VISIONARY study (EUPAS22204) included 87 patients from 7 ophthalmological centers in Russia with mean age of 63.9±11.8. Primary endpoint was mean IOP change at month 6. The patients were monitored for changes in in the severity of ocular signs and symptoms.

RESULTS

Statistically significant (p<0.0001) reduction of mean IOP from baseline was seen at all study visits: 7.3±5.17 mmHg at week 4, 7.4±5.40 mmHg at week 12, and 7.1±5.10 mmHg at month 6. By month 6, IOP has decreased by 20; 25; 30 and 35% from baseline in 77.0%, 58.9%, 43.7%, and 31.0% of study patients, respectively. Conjunctival hyperemia was significantly reduced at all study visits. Significant reductions in dry eye symptoms (p<0.0010), irritation (p=0.0204) and itching (p=0.0010) were also observed. After 6 months on PF tafluprost/timolol FC, 85.7% of patients described it as easy or very easy to tolerate.

CONCLUSION

In clinical practice, PF tafluprost/timolol FC provided statistically significant IOP reductions in patients with POAG and OH insufficiently controlled by or intolerant to monotherapy with topical beta-adrenoblockers or a prostaglandin analogue. The highest IOP reduction was seen at week 4 and was maintained over the 6-month study period. There was also a decrease in the severity of symptoms of ocular surface condition.

Keywords:

fixed-dose combination

glaucoma

ocular hypertension

preservative-free topical medication

tafluprost

timolol

Received:

20.05.2020

Accepted:

07.06.2020

Close metadata

References:

Oftal’mologiya. Natsional’noe rukovodstvo. Eds Avetisov S.E., Egorov E.A., Moshetova L.K., Neroev V.V., Takhchidi Kh.P. M.: GEOTAR-Media; 2018. (In Russ.).
Nagornova ZM, Seleznev AV, Zavadsky PCh, Kuroyedov AV. Choice regularities of antihypertensive therapy regimens of primary open-angle glaucoma in conditions of real clinical practice. Klinicheskaya oftal’mologiya. 2018;13:116-123. (In Russ.). https://doi.org/10.21689/2311-7729-2018-18-3-116-123
Kass M. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701-713. https://doi.org/10.1001/archopht.120.6.701
Chauhan B. Canadian Glaucoma Study. Arch Ophthalmol. 2008;126(8):1030. https://doi.org/10.1001/archopht.126.8.1030
Leske M, Heijl A, Hussein M, et al. Factors for glaucoma progression and the effect of treatment. Arch Ophthalmol. 2003;121(1):48-56. https://doi.org/10.1001/archopht.121.1.48
Bengtsson B, Leske M, Hyman L, Heijl A. Fluctuation of intraocular pressure and glaucoma progression in the early manifest glaucoma trial. Ophthalmology. 2007;114(2):205-209. https://doi.org/10.1016/j.ophtha.2006.07.060
Antonov AA, Agadzhanyan TM, Vitkov AA. Hypotensive efficacy of bimatoprost in the treatment of primary open-angle glaucoma. Natsional’nyi zhurnal glaukoma. 2019;18(1):95-104. (In Russ.). https://doi.org/10.25700/NJG.2019.01.11
Bettin P, Khaw PT (eds). Glaucoma Surgery. 2nd, revised and extended edition. Dev Ophthalmol. Basel, Karger; 2017;59:1-14. https://doi.org/10.1159/000458482
European Glaucoma Society: Terminology and Guidelines for Glaucoma. 4th ed. Savona: EGS; 2014.
Van der Valk R, Webers C, Schouten J, Zeegers M, Hendrikse F, Prins M. Intraocular pressure — lowering effects of all commonly used glaucoma drugs. Ophthalmology. 2005;112(7):1177-1185. https://doi.org/10.1016/j.ophtha.2005.01.042
Li T, Lindsley K, Rouse B, et al. Comparative effectiveness of first-line medications for primary open-angle glaucoma. Ophthalmology. 2016;123(1): 129-140. https://doi.org/10.1016/j.ophtha.2015.09.005
Baudouin C, Labbé A, Liang H, Pauly A, Brignole-Baudouin F. Preservatives in eyedrops: The good, the bad and the ugly. Prog Retin Eye Res. 2010; 29(4):312-334. https://doi.org/10.1016/j.preteyeres.2010.03.001
Neroev VV, Zolotarev AV, Karlova EV, Kiseleva OA, Shishkin MM, Germanova VN. Influence of treatment adherence on the progression of primary open-angle glaucoma in clinical setting. Vestnik oftal’mologii. 2019;135(6):49-57. (In Russ.). https://doi.org/10.17116/oftalma201913506149
Cox J, Mollan S, Bankart J, Robinson R. Efficacy of antiglaucoma fixed combination therapy versus unfixed components in reducing intraocular pressure: a systematic review. Brit J Ophthalmol. 2008;92(6):729-734. https://doi.org/10.1136/bjo.2008.139329
Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol. 2010;4:1-9. https://doi.org/10.2147/opth.s6645
Thygesen J. Glaucoma therapy: preservative-free for all? Clin Ophthalmol. 2018;12:707-717. https://doi.org/10.2147/opth.s150816
Oddone F, Tanga L, Kóthy P, et al. Treatment of Open-Angle Glaucoma and Ocular Hypertension with Preservative-Free Tafluprost/Timolol Fixed-Dose Combination Therapy: The VISIONARY (EUPAS22204) Study. Adv Ther. 2020;37:1436-1451. https://doi.org/10.1007/s12325-020-01239-8
Aptel F, Cucherat M, Denis P. Efficacy and tolerability of prostaglandin-timolol fixed combinations: a meta-analysis of randomized clinical trials. Eur J Ophthalmol. 2012;22(1):5-18. https://doi.org/10.5301/ejo.5000009
Konstas A, Katsanos A, Athanasopoulos G, et al. Preservative-free tafluprost/timolol fixed combination: comparative 24-h efficacy administered morning or evening in open-angle glaucoma patients. Expert Opin Pharmacother. 2018;19(18):1981-1988. https://doi.org/10.1080/14656566.2018.1534958
Pfeiffer N, Traverso C, Lorenz K, et al. A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components. Adv Ther. 2014;31(12):1228-1246. https://doi.org/10.1007/s12325-014-0163-3
Holló G, Hommer A, López A, Ropo A. Efficacy, safety, and tolerability of preservative-free fixed combination of tafluprost 0.0015%/timolol 0.5% versus concomitant use of the ingredients. J Ocul Pharmacol Therapeut. 2014; 30(6):468-475. https://doi.org/10.1089/jop.2013.0229
Spitzer E, Cannon C, Serruys P. Should real-world evidence be incorporated into regulatory approvals? Expert Opin Drug Saf. 2018;17(12):1155-1159. https://doi.org/10.1080/14740338.2018.1546842